Almirall Launches The Hive, Creating a Novel Collaborative Innovation Hub to Advance Life Sciences and Healthcare
Almirall, a global pharmaceutical company dedicated to medical dermatology, today announced the launch of “The Hive”, a novel scientific research hub located at its R&D centre in Barcelona, Spain. The Hive is designed to foster collaboration among researchers from biotech companies, start-ups, academia, and Almirall’s scientists, creating a unique innovation ecosystem that is aimed at advancing scientific breakthroughs and enhancing research success.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204100180/en/
From left upper row, to right: Marc Soriano, R&D Project Portfolio and Partnership, Lidia Martín, General Manager of Almirall Iberia, Antonio Gallardo, Jorge Gallardo, Dr. Karl Ziegelbauer, Chief Scientific Officer of Almirall, Meritxell Granell, Director of Institutional Relations, Raquel Yotti, PERTE Commissioner for Vanguard Health, Olga Pané, Consellera de Salut, Lourdes Borrell, Mayoress of Sant Feliu de Llobregat, Salvador Illa, President of the Generalitat de Catalunya, Carlos Gallardo, CEO and President of Almirall, Juan Cruz Cigudosa, Secretary of State for Science, Innovation and Universities, Núria Montserrat, Consellera de Recerca i Universitats, and Jaume Baró, Secretary for Business and Competitiveness of the Department of Business and Employment. (Photo: Business Wire)
The Hive builds on Almirall's open innovation centre, which began operations in 2023 with collaborations with two life science companies. The arrival of two new joiners announced today contribute to the creation of this unique collaboration ecosystem, following the initial partnerships with ZeClinics, a Contract Research Organization (CRO) specializing in genetics research using zebrafish as a model organism, and Centrient Pharmaceuticals, a global leader in sustainable biosynthetic pharmaceutical products.
The initiative was launched today as part of Almirall's 80th anniversary celebrations, bringing together health authorities, representatives from associations, entities, and institutions with whom Almirall closely collaborates to deliver against its commitment to patients, innovation, and the advancement of healthcare. The new joiners at The Hive include ADmit Therapeutics a company focused on the early detection of Alzheimer’s and other neurodegenerative diseases through technology that combines epigenetic and clinical data using machine learning. The most recent addition is Microomics a company specializing in metagenomic analysis using new DNA sequencing technologies (NGS).
"At Almirall, we bring together scientific experts from different disciplines in a collaborative environment as we see the transformative power collaboration has to push the boundaries of science and drive the development of novel solutions. An open innovation ecosystem that fosters this collaboration lays an exceptional foundation for breakthroughs in both scientific discovery and product development. We are proud to lead the way with The Hive, a unique initiative designed to advance science and innovation. By working together, we can address critical unmet needs and deliver meaningful progress in healthcare, ensuring that our innovations make a tangible difference in the lives of patients and their families", stated Dr. Karl Ziegelbauer, Almirall’s Chief Scientific Officer.
80 years of innovation and commitment to patients
Almirall is celebrating its 80th anniversary, marking eight decades of commitment to patients, innovation, and healthcare advancement. To commemorate this milestone, the company hosted an institutional event at its R&D centre in Barcelona, Spain. The event brought together health authorities, partners and institutional representatives, including the President of the Generalitat de Catalunya, Salvador Illa, Juan Cruz Cigudosa, Secretary of State for Science, Innovation, and Universities, María José Alonso, professor of Pharmacy and Pharmaceutical Technology at the University of Santiago de Compostela (USC), and Lourdes Borrell, Mayor of Sant Feliu de Llobregat.
Professor María José Alonso congratulated Almirall for its 80 decades “preserving the value of science and its transfer to industry in the best way, contributing to development and well-being, and elevating scientific value in the development of the Spanish innovative ecosystem, fostering a brighter future for all”.
Almirall was founded in Spain in 1944 with the purpose of giving people access to impactful medicines, a goal that continues to guide the company in its ambition as a leading medical dermatology. Almirall´s heritage, its deep scientific expertise, and the strong partnerships with the dermatology community worldwide are the foundation for its broad portfolio of dermatological treatments. Grounded in science and driven by innovation, the company continuously advances the understanding of skin diseases and provides solutions for even the most complex conditions. Based on this dedication, Almirall has become a leader in medical dermatology in Europe, with a strong portfolio of more than 50 products across different modalities, including topical, systemic, and biologics.
The company has invested 1 billion Euros in R&D in medical dermatology in the last decade which represents a continuous investment of over 12% of its annual net sales in R&D. This investment supports all phases of research conducted at its R&D centre – from discovery to late-stage clinical testing. Almirall’s close partnership with patients and dermatologists positions the company as a trusted and reliable partner, as it constantly focuses on understanding their needs to translate these into innovative solutions, helping improve people's lives both physically and emotionally.
Carlos Gallardo, Chairman and CEO of Almirall: "Celebrating 80 years is a testament to Almirall’s enduring commitment to innovation and patient care. Our journey has been driven by a profound dedication to improving patients' lives and providing meaningful treatments. As a family-owned company, we think in generations, and have consistently prioritized innovation in medical dermatology, investing over 1 billion Euros in R&D in this area over the last decade. We are grateful for the dedication of our teams across the company, and our partners and collaborators that enable us to help so many patients, every day. Our leading capabilities in skin biology and product development will continue to be a cornerstone of our mission, ensuring our sustained focus on science and innovation to deliver healthcare solutions to patients and the medical community."
About Almirall
Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients´ needs.
Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2023: €898.8 MM, 1900 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.
For more information, please visit https://www.almirall.com/
Legal notice:
This document includes only summary information and is not intended to be exhaustive. The facts, figures, and opinions contained in this document, in addition to the historical ones, are "forward-looking statements." These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals, or estimates contained in this document to reflect any changes in the assumptions, events, or circumstances on which such forward-looking statements are based, unless required by the applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241204100180/en/
Contacts
Corporate Communications:
corporate.communication@almirall.com
Phone: (+34) 659 614 173
Investor Relations
investors@almirall.com
Phone: (+34) 93 291 30 87
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mori Memorial Foundation Issues GPCI – 2024 and GPCI – Financial Centers Reports:10.12.2024 04:00:00 CET | Press Release
The Mori Memorial Foundation’s Institute for Urban Strategies, a research body established by Mori Building, Tokyo’s leading urban landscape developer, today released its Global Power City Index (GPCI) 2024 report on the overall strength of the world’s 48 major cities. For the second time, the report additionally includes the 'GPCI–Financial Centers' index. This index reflects the growing importance of measures taken by major cities to enhance their status as international financial centers, capturing changes in their financial and business environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209714811/en/ The 48 major cities evaluated in Mori Memorial Foundation’s GPCI–2024 Report (Graphic: Business Wire) More than 18 months have elapsed since the World Health Organization declared an end to the COVID-19 pandemic in May 2023. With the resurgence of economic activity, mobility and the expansion of international to
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA ® and Novel Pipeline Assets10.12.2024 02:30:00 CET | Press Release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne Medicines Ltd., today announced the presentation of new clinical data at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, underscoring its leadership in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) through continued clinical success with BRUKINSA® (zanubrutinib) and promising advancements in its pipeline assets. “The breadth of data we’re presenting at ASH underscores BRUKINSA’s role as a best-in-class treatment for CLL and highlights BeiGene’s leadership in advancing the treatment landscape for B-cell malignancies,” said Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. “BRUKINSA shows tremendous promise for patients as a monotherapy and as a backbone for best-in-class combinations. The combination of BRUKINSA and our investigational BCL2 inhibitor, sonrotoclax, demonstrated significant pot
Material Receives Splash Award for Outstanding Drupal Website10.12.2024 02:00:00 CET | Press Release
Material, a leading insights, marketing and technology company, is pleased to announce it is the recipient of the Splash Award in the “Education” category for work with INSEAD – The Business School for the World® and runner-up in the “Corporate” category for work with Stuff Limited. The first-ever DrupalCon Singapore Splash Awards celebrate outstanding websites and digital experiences built with Drupal, highlighting the creativity, technical excellence and innovative solutions agencies and developers bring to diverse industries and challenges. For the award-winning “Education” work, Material partnered with INSEAD to enhance the school’s overall digital presence, improve engagement and strengthen brand identity, aligning technology with business strategy to drive growth and success. Leveraging the latest Drupal technology, Material helped INSEAD increase conversion and retention rates, streamline user journeys and improve site usability. “Receiving the Splash Awards showcases Material’s
Bardstown Bourbon Company and Brindiamo Expand Relationship with First-of-its-kind Barrel Leasing Program9.12.2024 20:21:00 CET | Press Release
Bardstown Bourbon Company, the leading custom American whiskey distiller and Brindiamo, the global leader in sourcing bulk whiskey, today announced an exclusive relationship to provide a market-leading barrel leasing program for whiskey brand contract distillation customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209024956/en/ Bardstown Bourbon Company, the leading custom American whiskey distiller and Brindiamo, the global leader in sourcing bulk whiskey, will launch an exclusive barrel leasing program -- a timely, tailored solution for non-distilling brands. Roughly one-third of the cost of a new fill barrel is tied up in the wood used to make the barrel. This program allows brands to simplify this significant upfront expense into manageable monthly payments, offering customers the flexibility to plan for tomorrow while maintaining the cashflow to support their needs today. (Photo: Business Wire) As the whiskey
Bynder Kicks Off Peak Shopping Season by Serving a Record 6 Billion Assets - Powering Exceptional Global Content Experiences Online9.12.2024 16:07:00 CET | Press Release
Bynder, a global leader in AI-powered enterprise DAM, has helped a number of global brands break Black Friday and Cyber Monday records by delivering exceptional content experiences at scale across a number of worldwide e-commerce channels. During the seven day period (November 27 - Dec 2 2024) which included Black Friday, Small Business Saturday, and Cyber Monday, Bynder’s Content Experiences (CX) for Omnichannel solution was responsible for serving more than 6 billion assets to over 70,000 websites, with more than 4.5 billion asset transformations undertaken. The figures represent a 15% increase in assets delivered vs 2023, plus 67% more assets were delivered through CX for Omnichannel on Black Friday than an average day in 2024. Customers such as Sur La Table, Bose, Raymour & Flanigan and Puma used CX for Omnichannel to deliver targeted and optimized content at scale to their digital channels over the busiest shopping days. Bynder customers were able to utilize the assets stored in t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom